Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

stroke prevention

  • Home
  • stroke prevention
  • Page 2
Low-Dose Apixaban vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: Insights from the ADALA Trial
Posted inCardiology Clinical Updates news Specialties

Low-Dose Apixaban vs Dual Antiplatelet Therapy After Left Atrial Appendage Occlusion: Insights from the ADALA Trial

Posted by MedXY By MedXY 09/20/2025
The ADALA randomized trial compared low-dose apixaban with dual antiplatelet therapy post-LAA occlusion, demonstrating superior safety and reduced device-related thrombosis risk with low-dose anticoagulation at 3 months.
Read More
Biomarker-Guided ABC-AF Risk Scores: Evaluating Their Role in Personalized Therapy for Atrial Fibrillation
Posted inClinical Updates news

Biomarker-Guided ABC-AF Risk Scores: Evaluating Their Role in Personalized Therapy for Atrial Fibrillation

Posted by MedXY By MedXY 09/06/2025
A large randomized study found that biomarker-based ABC-AF risk score-guided therapy did not improve stroke or death outcomes versus usual care in atrial fibrillation, highlighting the need for rigorous prospective validation of precision medicine tools before clinical adoption.
Read More
Biomarker-Guided ABC-AF Risk Scores in Atrial Fibrillation: Insights from a Large Multicenter Randomized Trial
Posted inCardiology news Pathology & Lab Medicine Specialties

Biomarker-Guided ABC-AF Risk Scores in Atrial Fibrillation: Insights from a Large Multicenter Randomized Trial

Posted by MedXY By MedXY 09/06/2025
A biomarker-based ABC-AF risk score-guided treatment did not improve stroke or death outcomes versus standard care in atrial fibrillation, underscoring the need for prospective validation of precision medicine tools before clinical implementation.
Read More
Reevaluating Long-Term Anticoagulation After Atrial Fibrillation Ablation: Insights from the ALONE-AF Randomized Trial
Posted inCardiology Specialties

Reevaluating Long-Term Anticoagulation After Atrial Fibrillation Ablation: Insights from the ALONE-AF Randomized Trial

Posted by MedXY By MedXY 09/01/2025
The ALONE-AF trial reveals that discontinuation of oral anticoagulants post-successful atrial fibrillation ablation may reduce stroke, systemic embolism, and major bleeding compared to continued therapy, informing anticoagulation strategies in selected patients.
Read More
Edoxaban as a Safe and Effective Anticoagulant Early After Bioprosthetic Valve Replacement: Insights from the ENBALV Trial
Posted inCardiology Specialties

Edoxaban as a Safe and Effective Anticoagulant Early After Bioprosthetic Valve Replacement: Insights from the ENBALV Trial

Posted by MedXY By MedXY 08/17/2025
The ENBALV randomized trial demonstrates that edoxaban offers a potential safe and efficacious alternative to warfarin for anticoagulation within three months after surgical bioprosthetic valve replacement, with comparable thromboembolic event rates and a distinct safety profile.
Read More
Can High Pillows Trigger Stroke? Understanding the Causes of Brain Stroke
Posted inNeurology news Specialties

Can High Pillows Trigger Stroke? Understanding the Causes of Brain Stroke

Posted by MedXY By MedXY 08/08/2025
This article explores how excessively high pillows may increase stroke risk by affecting neck blood vessels, discusses other stroke risk factors, and offers guidance on pillow choice and sleep positions for better health.
Read More
Recognizing and Preventing Insufficient Blood Supply to the Brain
Posted inCardiology news Specialties

Recognizing and Preventing Insufficient Blood Supply to the Brain

Posted by MedXY By MedXY 08/04/2025
Learn about the symptoms of reduced blood flow to the brain and practical ways to prevent serious complications like stroke.
Read More
Routine Use of Cerebral Embolic Protection in TAVI: Evidence, Outcomes, and Clinical Implications
Posted inCardiology Clinical Updates news Specialties

Routine Use of Cerebral Embolic Protection in TAVI: Evidence, Outcomes, and Clinical Implications

Posted by MedXY By MedXY 08/01/2025
Large-scale trials show that routine cerebral embolic protection during TAVI does not significantly reduce early stroke rates, though selective benefits in major stroke and secondary outcomes may exist.
Read More
Balancing Stroke Prevention and Bleeding Risk: Timing of DOAC Restart After Serious Bleeding in Atrial Fibrillation
Posted inCardiology Clinical Updates news Specialties

Balancing Stroke Prevention and Bleeding Risk: Timing of DOAC Restart After Serious Bleeding in Atrial Fibrillation

Posted by MedXY By MedXY 07/31/2025
Early resumption of DOACs after serious bleeding in AF patients may lower stroke risk but significantly increases recurrent bleeding. Individualized decision-making and further research are recommended.
Read More

Posts pagination

Previous page 1 2
  • Digital Vestibular Rehabilitation After Acute Vertigo: What a Negative Superiority Trial Means
  • Restoring Cortisol Rhythm May Be Key to Recovery After Cushing Syndrome
  • Long-term Follow-up of Type 1 Diabetes Immunotherapy Trials Finds Reassuring Safety Signals
  • Long-Term Safety Signals Remain Reassuring in Type 1 Diabetes Immunotherapy Follow-up
  • Mitochondrial Rescue in HFpEF: Elamipretide Restores Skeletal Muscle Performance in a Rat Model
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health quality of life randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in